Health Condition 1: null- Osteoarthritis
Conditions
Sponsors
Central Council for Research in Ayurvedic Sciences CCRAS
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with Primary Osteoarthritis (Diagnosis to be confirmed by Kellgren Lawrence Radiological scale) 2. Pain in the affected joint(s) > six weeks. 3. Willing and able to participate in the study.
Exclusion criteria
Exclusion criteria: 1. History of any surgical /diagnostic intervention with reference to the affected joint(s). 2. Patients who are incapacitated, bedridden or confined to a wheelchair. 3. Patients with co morbidities such as gouty arthritis, rheumatoid arthritis and psoriatic arthritis 4. Patients having any deformity of knee, hip or back. 5. Patients with poorly controlled Hypertension ( >160/100 mm of Hg) 6. Patients with Diabetes Mellitus {B.S. (F) > 126 mg% and / or B.S. (2 hr. PP) >200 mg% or HbA1c > 6.5%}. 7. Patients with evidence of malignancy. 8. Patients on prolonged ( > 6 weeks) medication with corticosteroids, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study. 9. Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months. 10. Symptomatic patients with clinical evidence of Heart failure. 11. Patients with concurrent serious hepatic disorder (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) > 2 times upper normal limit) or Renal Disorders (defined as S. Creatinine >1.2mg/dL), Severe Pulmonary Dysfunction (uncontrolled Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease [COPD]), or any other condition that may jeopardize the study. 12. Alcoholics and/or drug abusers. 13. H/o hypersensitivity to any of the trial drugs or their ingredients. 14. Pregnant / lactating woman. 15. Patients who have completed participation in any other clinical trial during the past six (06) months. 16. Any other condition which the Principal Investigator thinks may jeopardize the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in WOMAC total scoreTimepoint: At Baseline, 14th day, 28th day, 42nd day, 56th day, 70th day, 84th day and at the end of follow up after 14 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in Patientâ??s Global Assessment of the Disease Activity ScaleTimepoint: At Baseline, 14th day, 28th day, 42nd day, 56th day, 70th day, 84th day and at the end of follow up after 14 weeks;Change in WOMAC Physical function DomainTimepoint: At Baseline, 14th day, 28th day, 42nd day, 56th day, 70th day, 84th day and at the end of follow up after 14 weeks;Change in WOMAC stiffness Domain ScoreTimepoint: At Baseline, 14th day, 28th day, 42nd day, 56th day, 70th day, 84th day and at the end of follow up after 14 weeks | — |
Countries
India
Contacts
Public ContactDr Pradeep Dua
Central Council for Research in Ayurvedic Sciences (CCRAS)
Outcome results
None listed